Pulmonx (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 12,237 Shares

Pulmonx Corporation (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 12,237 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $17,498.91. Following the sale, the general counsel directly owned 240,755 shares of the company’s stock, valued at approximately $344,279.65. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulmonx Stock Up 13.5%

NASDAQ LUNG traded up $0.20 during trading hours on Thursday, hitting $1.64. The company’s stock had a trading volume of 1,488,051 shares, compared to its average volume of 391,899. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. The company’s 50-day simple moving average is $1.77 and its two-hundred day simple moving average is $1.79. The company has a market capitalization of $67.44 million, a PE ratio of -1.16 and a beta of 0.07. Pulmonx Corporation has a 52 week low of $1.31 and a 52 week high of $8.12.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%.The company had revenue of $22.60 million for the quarter, compared to analyst estimates of $21.73 million. Research analysts anticipate that Pulmonx Corporation will post -1.55 EPS for the current fiscal year.

Pulmonx News Roundup

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Closed a up-to-$60 million, five-year credit facility with Perceptive Advisors that includes an initial $40M draw to refinance existing debt, extends maturity to 2031 and provides an undrawn $20M option tied to milestones — improves liquidity runway and capital structure. Credit Facility Announcement
• Positive Sentiment: Q4 results beat expectations: EPS -$0.25 vs. consensus -$0.39 and revenue $22.6M vs. ~$21.7M — loss narrowed vs prior year and adjusted EBITDA improved, which supports the company’s operational progress. Earnings Report
• Positive Sentiment: D. Boral Capital reiterated a “Buy” rating with a $14 price target (large upside vs current levels) — analyst support can attract buyers and improve sentiment. Analyst Reaffirmation
• Neutral Sentiment: Q4 gross margin improved to ~78% and operating expenses fell ~11% year-over-year in the quarter — margin recovery and cost cuts are constructive but need revenue re-acceleration to translate into sustained profitability. Quarterly Results Release
• Negative Sentiment: 2026 revenue guidance of $90M–$92M comes in below consensus (~$94.1M), signaling slower near-term top-line growth and limiting upside despite cost cuts. Guidance Disclosure
• Negative Sentiment: Multiple insiders (including the CEO and general counsel) sold shares on March 2 — notable insider selling can be viewed negatively by the market. SEC filing links show the transactions. CEO Form 4
• Negative Sentiment: The new financing carries a high effective cost (one-month SOFR + 7.0% with a 3.75% floor, and 2% PIK option) and includes milestone-linked access to the additional $20M — helpful for liquidity but raises interest expense and conditionality/dilution concerns. Facility Analysis
• Negative Sentiment: Reports that the company issued warrants as part of recent financing (term loan/warrants) raise potential dilution risk if exercised. Loan & Warrants Report

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.81.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ExodusPoint Capital Management LP purchased a new position in Pulmonx during the fourth quarter worth about $4,312,000. Vestal Point Capital LP bought a new stake in shares of Pulmonx during the 3rd quarter valued at about $1,345,000. State Street Corp boosted its position in shares of Pulmonx by 3.6% during the 4th quarter. State Street Corp now owns 821,217 shares of the company’s stock valued at $1,815,000 after acquiring an additional 28,813 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Pulmonx by 78.3% during the 3rd quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock valued at $1,224,000 after acquiring an additional 331,742 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.